分组1 - Voyager Therapeutics reported a quarterly loss of $0.46 per share, better than the Zacks Consensus Estimate of a loss of $0.54, and improved from a loss of $0.59 per share a year ago, resulting in an earnings surprise of +15.08% [1] - The company posted revenues of $15.34 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 57.97%, compared to revenues of $6.28 million in the same quarter last year [2] - Voyager Therapeutics has surpassed consensus EPS estimates two times over the last four quarters and has also topped consensus revenue estimates twice during the same period [2] 分组2 - The stock has lost about 0.8% since the beginning of the year, while the S&P 500 has declined by 1.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.40 on revenues of $9.65 million, and for the current fiscal year, it is -$1.39 on revenues of $84.73 million [7] - The Medical - Biomedical and Genetics industry, to which Voyager Therapeutics belongs, is currently in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]